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Complex regional pain syndrome (CRPS) is a disorder characterized by an intractable, disabling pain of the affected
limb. It is triggered by various injuries and is often resistant to standard therapy. We report a young soldier with
CRPS of the right hand sustained from an electrical injury, who had improvement in resting pain with Zoledronic
acid. In this report, we discuss the therapeutic options and the role of bisphosphonates in CRPS.
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Complex regional pain syndrome (previously termed re-
flex sympathetic dystrophy syndrome) is a condition that
is characterized by pain, swelling, vasomotor changes,
allodynia and regional osteoporosis. The disease is caused
by a multitude of etiologies, including direct injury to
nerves or limbs [1]. Complex regional pain syndrome
(CRPS) is divided into two types based on the presence
(CRPS II) or absence (CRPS I) of demonstrable nerve
lesion. The pathophysiological basis of the disease is
poorly documented, and it basically involves an aberrant
host response to tissue injury [2]. The clinical hetero-
geneity of the disease is reflected in the resistance of this
condition to the various available therapeutic options
for the disorder.
Electrical injuries are common in clinical practice be-
cause of the accidental exposure to low voltage (<500 V)
domestic circuits. The pattern of injuries differs based
on the voltage (low or high), electricity source (lightning
or electrical) and electricity type (alternating or direct)
[3]. The acute effects of electrical injuries are burns, car-
diac arrhythmias, myoglobinuria and sudden cardiore-
spiratory arrest [4]. Delayed neurological manifestations,
including CRPS, predominate during the chronic phase
after an electrical injury [5]. We recently encountered a
soldier who reported to us with features of CRPS after
sustaining a domestic electrical injury that improved
with bisphosphonates. We report this case to highlight* Correspondence: hariendo@rediffmail.com
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in the treatment of resistant cases of CRPS.Case presentation
A 34-year-old man was referred to our hospital in May
2014 with a history of pain and swelling of the right
hand for a duration of 3 months. The patient sustained
an electrical shock to the right hand while repairing a
domestic electrical appliance. He denied any cutaneous
injury, loss of consciousness or injury to any other body
part due to the electrical shock. He noticed pain in his
right hand within one week of injury, which was treated
with analgesics without relief. He noticed a subsequent
swelling, deep aching pain, cutaneous hypersensitivity
and discoloration of the right hand. The patient denied
aggravation of symptoms during exposure to cold or any
diurnal variation of the symptoms. The patient indicated
severe pain, which he rated as 9 on a 10-point visual
analogue scale (VAS). He was treated with a short
course of oral prednisolone with physiotherapy at a per-
ipheral hospital, but the improvement was not signifi-
cant. The patient is employed as an infantry soldier, and
the condition prevented him from being able to handle
any weapons. He was also unable to use his right hand
for activities of daily living. The patient denied alcohol
consumption or tobacco use, and his previous medical
history was unremarkable. Examination revealed stable vital
parameters, and systemic examination was unremarkable.
His right hand was markedly tender, hyperemic with diffuse
swelling and cutaneous hypersensitivity (Figure 1). Other
vasomotor changes were absent, and the radial pulse wasentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Swollen right hand showing hyperemia.
Figure 2 DEXA scan showing regional osteoporosis of right hand
bones with juxta articular osteopenia (arrows).
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not apparent, and there was generalized weakness of the
hand muscles, likely because of the reduced effort by the
patient.
His hematological and biochemical parameters were all
normal, including the C-reactive protein, creatine kinase,
calcium, phosphorus, alkaline phosphatase and 25-hydroxy
vitamin D levels. A nerve conduction study and electro-
myography of the left upper extremity showed no evidence
of neuropathy or myopathy. A Dual Energy X-ray Absorp-
tiometry (DEXA) scan revealed a significant reduction in
bone mass of the right side (0.47 g/cm2) compared to the
left (1.1 g/cm2) side (Figure 2). He was diagnosed as a case
of CRPS type I based on the clinical features, and he was
treated with Zoledronic acid (4 mg, intravenously once
monthly). Zoledronic acid was considered the best option
in our patient because of the failure of conventional therap-
ies, including analgesics, glucocorticoids and physiother-
apy. He experienced partial pain relief over the next 7 days,
and he rated the current pain as 5/10 on the VAS. He was
given a repeat injection of Zoledronic acid after one month,
and the pain during the last follow-up was reduced to 2/10
VAS with a complete reduction of the swelling. He started
handling and firing fire arms last month, but he is unable
to use his right arm completely for all activities. Currently,
the patient has no resting pain, and he is able to use the
right hand for all activities of daily living. However, the
patient has mild pain during prolonged use of the hand,
and he is unable to lift heavy objects using the right
hand. We did not evaluate the upper hand disability
initially with an objective assessment for comparison
after treatment. Currently, the patient has no resting
pain, but he has minimal pain with prolonged use of
the limb muscles. A repeat DEXA scan at the end of
3 months revealed minimal improvement in bone mass
(0.78 g/cm2) on the right side.Discussion
Complex Regional Pain Syndrome (CRPS) is a disorder
that is characterized by intense pain in association with
sensory, motor, autonomic and trophic abnormalities
[1]. A variety of pathophysiological insults trigger CRPS,
and the condition is often resistant to therapy, which ne-
cessitates a multimodal approach. Electrical injuries are
rarely reported as an etiological factor in CRPS [3]. Elec-
trical injuries result in neurological damage during acute
and chronic stages. Acute effects include paralysis, neur-
opathy and chronic effects, such as vertigo, tinnitus,
depression and tremors [6]. The DASH (Disabilities of
the Arm, Shoulder and Hand) questionnaire is a self-
reported measure to assess disabilities that are specific
to the upper extremities [7]. Unfortunately, we did not
assess disability using the DASH scale prior to the Zole-
dronic acid therapy, which limited an objective assess-
ment. Previous reports suggest that more than half of
CRPS patients have a persistent long-lasting disability
despite therapy [8]. Our patient exhibited a persistent
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after therapy.
Electrical injury rarely results in CRPS, and this type
of injury mostly leads to CRPS II rather than CRPS I [9].
CRPS I and II are neuropathic conditions, but the lack
of demonstrable neuropathy on nerve conduction study
in our patient precluded the diagnosis of CRPS II. Our
patient did not exhibit features of myopathy on the
EMG. Therefore, we did not consider the possibility of a
direct muscle injury from the electrical insult. The use of
EMG is fraught with limitations of availability and inter-
pretation. Assessment for muscle atrophy is performed
using clinical (measurement of girth) and radiological
(ultrasonography) methods. Subclinical muscular atrophy
is identified by a reduced bulk and increased echogenicity
of muscles on ultrasonography [10]. Nerve and muscle
injury may have contributed to the muscle atrophy after
an electrical shock. Unfortunately, we did not perform
ultrasonography of the muscle to identify subclinical
muscular atrophy. The pathophysiological basis of CRPS
is poorly understood, and the disease is characterized by
a high turnover of bone and regional bone loss. The dis-
ease is caused by neurogenic inflammation, nociceptive
sensitization, vasomotor dysfunction and maladaptation
of neuroplasticity [1]. Other novel pathogenic mecha-
nisms are implicated in CRPS, including the formation
of multiple myofascial trigger points and the intermit-
tent release of inflammatory mediators due to repeated
movement [11,12].
CRPS is not easily amenable to therapy despite the
availability of multiple therapeutic modes. The thera-
peutic approach involves the use of nonsteroidal anti-
inflammatory drugs, narcotic analgesics, corticosteroids,
calcitonin, serotonin reuptake inhibitors, bisphospho-
nates and sympathetic blocks [2]. The patients often re-
quire multiple therapeutic modalities of therapy, and
CRPS may persist in a majority of patients despite the
use of all remedial measures. Fortunately, our patient
showed significant resolution of his symptoms after
Zoledronic acid, which limited the necessity of other
therapeutic options. Few investigators have used neu-
romodulation techniques, such as stimulation of per-
ipheral nerves, spinal cord, motor cortex, and deep
brain, and intrathecal drug delivery systems in resistant
cases of CRPS [13]. Bisphosphonates potently inhibit
bone turnover, and these drugs are useful in all cases of
CRPS I [14]. A previous trial using intravenous neridro-
nate in a similar situation of early CRPS showed a >50%
reduction in the pain VAS score in 73% of patients versus
32% in the placebo group [15]. The reduction of pain is
associated with decreased allodynia, hyperalgesia and
improvements in pain-related quality of life indices.
Bisphosphonates relieve the pain associated with CRPS
by reducing the osteoclast activity and the release ofnociceptive mediators. The term “Orphan medicinal
products” is used for drugs that are under evaluation
and may be useful in rare disorders based on their
physiological actions. Zoledronic acid has been given an
orphan designation in the United States, but not in the
European Union, for its use in CRPS [16].
Conclusion
We report a patient with CRPS I who presented after an
electrical injury and showed a good response to the use
of intravenous Zoledronic acid. Our report highlights
the beneficial role of bisphosphonates in the few CRPS
patients who are resistant to standard therapy.
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